Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMMX NASDAQ:MRKR NASDAQ:SKYE NASDAQ:TNYA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMMXImmix Biopharma$2.97+1.7%$2.34$1.26▼$3.12$82.79M0.24153,736 shs278,471 shsMRKRMarker Therapeutics$1.70-11.5%$1.46$0.95▼$5.95$19.24M1.43343,523 shs1.77 million shsSKYESkye Bioscience$3.89+4.6%$2.99$1.14▼$7.47$120.49M1.95513,462 shs320,616 shsTNYATenaya Therapeutics$0.88+1.3%$0.57$0.36▼$4.06$142.68M32.81 million shs4.27 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMMXImmix Biopharma0.00%+12.08%+24.27%+78.92%+36.24%MRKRMarker Therapeutics0.00%-0.58%+15.65%+47.83%-71.48%SKYESkye Bioscience0.00%-2.26%+81.78%+171.08%-38.35%TNYATenaya Therapeutics0.00%+28.38%+51.62%+94.91%-75.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMMXImmix Biopharma3.1116 of 5 stars3.55.00.00.00.03.30.6MRKRMarker Therapeutics4.1838 of 5 stars3.85.00.03.90.60.80.6SKYESkye Bioscience1.7758 of 5 stars3.54.00.00.01.10.00.0TNYATenaya Therapeutics3.2794 of 5 stars3.53.00.00.00.64.21.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMMXImmix Biopharma 3.00Buy$7.00135.69% UpsideMRKRMarker Therapeutics 3.50Strong Buy$13.17674.51% UpsideSKYESkye Bioscience 3.00Buy$16.60326.74% UpsideTNYATenaya Therapeutics 3.00Buy$6.25612.58% UpsideCurrent Analyst Ratings BreakdownLatest MRKR, SKYE, TNYA, and IMMX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025SKYESkye BioscienceJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$15.006/4/2025IMMXImmix BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.005/20/2025SKYESkye BioscienceWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/9/2025TNYATenaya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/25/2025TNYATenaya TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMMXImmix BiopharmaN/AN/AN/AN/A$0.48 per shareN/AMRKRMarker Therapeutics$6.59M2.92N/AN/A$1.73 per share0.98SKYESkye BioscienceN/AN/AN/AN/A$2.25 per shareN/ATNYATenaya TherapeuticsN/AN/AN/AN/A$1.07 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMMXImmix Biopharma-$21.61M-$0.70N/AN/AN/AN/A-130.02%-86.33%8/11/2025 (Estimated)MRKRMarker Therapeutics-$10.73M-$1.33N/AN/AN/A-224.46%-101.87%-83.02%8/13/2025 (Estimated)SKYESkye Bioscience-$26.57M-$0.82N/AN/AN/AN/A-53.92%-48.58%N/ATNYATenaya Therapeutics-$111.13M-$1.16N/AN/AN/AN/A-92.20%-74.53%8/14/2025 (Estimated)Latest MRKR, SKYE, TNYA, and IMMX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025TNYATenaya Therapeutics-$0.17N/AN/AN/AN/AN/A8/13/2025Q2 2025MRKRMarker Therapeutics-$0.55N/AN/AN/A$0.72 millionN/A8/11/2025Q1 2025IMMXImmix Biopharma-$0.21N/AN/AN/AN/AN/A5/8/2025Q1 2025SKYESkye Bioscience-$0.31-$0.28+$0.03-$0.28N/AN/A5/7/2025Q1 2025TNYATenaya Therapeutics-$0.18-$0.24-$0.06-$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMMXImmix BiopharmaN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/ASKYESkye BioscienceN/AN/AN/AN/AN/ATNYATenaya TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMMXImmix BiopharmaN/A1.801.80MRKRMarker TherapeuticsN/A6.796.79SKYESkye BioscienceN/A11.8511.85TNYATenaya TherapeuticsN/A6.686.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMMXImmix Biopharma11.26%MRKRMarker Therapeutics22.39%SKYESkye Bioscience21.09%TNYATenaya Therapeutics90.54%Insider OwnershipCompanyInsider OwnershipIMMXImmix Biopharma55.40%MRKRMarker Therapeutics14.50%SKYESkye Bioscience4.50%TNYATenaya Therapeutics48.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMMXImmix Biopharma927.88 million12.43 millionOptionableMRKRMarker Therapeutics6011.31 million9.67 millionNot OptionableSKYESkye Bioscience1130.98 million29.58 millionOptionableTNYATenaya Therapeutics110162.67 million83.53 millionOptionableMRKR, SKYE, TNYA, and IMMX HeadlinesRecent News About These CompaniesBrokerages Set Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Price Target at $6.25July 10, 2025 | americanbankingnews.comTNYA - Tenaya Therapeutics Inc Dividends - MorningstarJuly 8, 2025 | morningstar.comMTNYA - Tenaya Therapeutics Inc Trailing Returns - MorningstarJuly 8, 2025 | morningstar.comMTenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Consensus Rating of "Buy" from AnalystsJuly 7, 2025 | marketbeat.comTenaya Therapeutics (NASDAQ:TNYA) Stock Price Down 0.3% - Here's WhyJuly 4, 2025 | marketbeat.comTenaya Therapeutics, Inc. (TNYA) Balance Sheet - Yahoo FinanceJune 27, 2025 | finance.yahoo.comTenaya Therapeutics, Inc. (TNYA) Cash Flow - Yahoo FinanceJune 27, 2025 | finance.yahoo.comTenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)May 16, 2025 | finanznachrichten.deTenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)May 15, 2025 | globenewswire.comWhy Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 5.10%May 15, 2025 | aaii.comATenaya Therapeutics to Present Five Abstracts on Innovative Heart Disease Gene Therapies at ASGCT 2025 Annual MeetingMay 15, 2025 | nasdaq.comTenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual MeetingMay 13, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL), Stevanato Group (STVN) and Tenaya Therapeutics (TNYA)May 11, 2025 | theglobeandmail.comWe're A Little Worried About Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn RateMay 10, 2025 | finance.yahoo.comTenaya Therapeutics Reports Q1 2025 Financial ResultsMay 8, 2025 | tipranks.comTenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 7, 2025 | finance.yahoo.comWhy Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Up 5.03%May 2, 2025 | aaii.comAWhy Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 6.21%April 30, 2025 | aaii.comAH.C. Wainwright maintains Buy on Tenaya Therapeutics stockApril 26, 2025 | investing.comWhy Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Up 6.36%April 26, 2025 | aaii.comATenaya announces interim data from ongoing RIDGE studyApril 25, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMRKR, SKYE, TNYA, and IMMX Company DescriptionsImmix Biopharma NASDAQ:IMMX$2.97 +0.05 (+1.71%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$2.91 -0.06 (-2.02%) As of 07/18/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.Marker Therapeutics NASDAQ:MRKR$1.70 -0.22 (-11.46%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.70 0.00 (0.00%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.Skye Bioscience NASDAQ:SKYE$3.89 +0.17 (+4.57%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$3.92 +0.03 (+0.77%) As of 07/18/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.Tenaya Therapeutics NASDAQ:TNYA$0.88 +0.01 (+1.27%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.86 -0.02 (-2.41%) As of 07/18/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
